Dr. Gibney is actively involved translational research in targeted therapies for melanoma and other skin cancers to develop personalized treatment strategies. He is investigating the role of receptor tyrosine kinases and intracellular proteins as biomarkers and therapeutic targets in cutaneous malignancies. This includes specific research in c-Met, Axl, PDGF-ß and the JAK2/STAT3 pathways in melanoma. He is also interested in integrating targeted therapeutics with immunotherapies.
In addition to translational research, he is the principle investigator of multiple clinical trials for melanoma therapies at Moffitt Cancer Center. He has a specific interest in treating patients with melanoma brain metastases and is a co-leader of the Neuro Melanoma program at Moffitt. He also treats patients with advanced non-melanoma skin cancers, such as basal cell carcinoma, squamous cell carcinoma, and merkel cell carcinoma.